A09
Project Area A - Biology and Molecular Oncology
Prof. Dr. Christian Reinhardt
Clinic for Hematology and Stem Cell Transplantation
University Hospital Essen
Phone: +49 201 723 3136
Email
Targeting oncogene-induced DNA repair pathway switches
Reinhardt has identified a cell state transition in KRAS-driven non-small cell lung cancer cells that features a critical change in DNA damage repair competence accompanied with increased mutational burden and altered cancer drug sensitivities. He will unravel the molecular role of proteins of the ubiquilin family that mediate this transition, identify the gene regulatory elements that trigger ubiquilin overexpression and dissect the mechanism and additional targets of the ubiquilins using proteomics. In addition to these mechanistic studies, he will determine thera-peutic vulnerabilities in vitro and in mouse models.
Project Members
Dr. Svenja Höfmann
Publications
-
CSF1R⁺ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphomaIn: Cancer Cell, Vol. 43, 2025, Nr. 8, pp. 1476 – 1494.e10DOI (Open Access)
-
Lymphoma accelerates T cell and tissue agingIn: Cancer Cell, Vol. 43, 2025, Nr. 10, pp. 1917 – 1936.e8DOI (Open Access)
-
A novel mouse model recapitulating the MMR-defective SCLC subtype uncovers an actionable sensitivity to immune checkpoint blockadeIn: Journal of Cancer Research and Clinical Oncology, Vol. 150, 2024, Nr. 11, 496DOI (Open Access)
-
An inducible Cd79b mutation confers ibrutinib sensitivity in mouse models of Myd88-driven diffuse large B-cell lymphomaIn: Blood Advances, Vol. 8, 2024, Nr. 5, pp. 1063 – 1074DOI (Open Access)
-
Cranioencephalic functional lymphoid units in glioblastomaIn: Nature Medicine, Vol. 30, 2024, Nr. 10, pp. 2947 – 2956DOI (Open Access)
-
Noninvasive minimal residual disease assessment in relapsed/refractory large B-cell lymphoma using digital droplet PCRIn: European Journal of Haematology, Vol. 112, 2024, Nr. 6, pp. 957 – 963DOI (Open Access)
-
Distinct genetically-determined origins of Myd88/Bcl2-driven aggressive lymphoma rationalize targeted therapeutic intervention strategiesIn: Blood Cancer Discovery, Vol. 4, 2023, Nr. 1, pp. 78 – 97DOI (Open Access)
-
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanomaIn: Nature Cancer, Vol. 4, 2023, Nr. 9, pp. 1292 – 1308DOI (Open Access)
-
An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal LymphomasIn: Cancer Discovery. Philadelphia: American Association for Cancer Research (AACR), Vol. 13, 2023, Nr. 1, pp. 216 – 243DOI, Online Full Text (Open Access)